VSTM (Verastem) Moat Score: 5/10 (As of Jun. 26, 2026)


VSTM Verastem Inc VSTM
11 GF Score
Price $3.59
! 7 Warning Signs
View Full Analysis

What is Verastem Moat Score?

Verastem VSTM +4.06% 11 Moat Score is 5 as of Jun. 26, 2026. GuruFocus rates VSTM with a GF Score™ of 11/100. The stock has 7 warning signs investors should review. Among 1,404 Biotechnology companies, Verastem ranks better than 96.72% on this metric.

Verastem has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Verastem has Narrow Moat: Verastem Inc has a solid narrow moat with valuable intellectual property in oncology treatments. However, it faces intense competition and regulatory challenges, limiting its overall competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Verastem might have Narrow Moat - Solid narrow moat.

Verastem  (NAS:VSTM) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Verastem Moat Score Related Terms

VSTM vs ENTA, ARTV, IMRX: Moat Score Comparison

For the Biotechnology subindustry, Verastem's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verastem Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verastem's Moat Score distribution charts can be found below:

* The bar in red indicates where Verastem's Moat Score falls into.


VSTM
11GF Score
Verastem Inc VSTM
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Verastem (VSTM) has a Moat Score of 5 as of Jun. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Verastem ranks #46 out of 1404 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Verastem's Moat Score too high?
Verastem's current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Verastem's value of 5 is 150% above this industry median. Based on the distribution chart, Verastem ranks #46 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Verastem has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Verastem's Moat Score compare to ENTA and ARTV?
According to the Biotechnology industry distribution chart, Verastem ranks #46 out of 1404 companies for Moat Score. This places Verastem in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Verastem's value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Verastem's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verastem's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verastem stock overvalued right now?
Verastem (VSTM) has a current Moat Score of 5. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Verastem's overall GF Score™ is 11/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Verastem (VSTM), the current Moat Score is 5 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Verastem Business Description

Other Exchanges 0LOV:UK2VS:Germany
Address 117 Kendrick Street, Suite 500, Needham, MA, USA, 02494
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
11GF Score

Get the complete analysis for VSTM

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.59
Price